A new diethylcarbamazine formulation (NANO-DEC) as a therapeutic tool for hepatic fibrosis

dc.creatorRodrigues, Gabriel Barros
dc.creatorOliveira, Elquio Eleamen
dc.creatorMendonça Junior, Francisco Jaime Bezerra
dc.creatorSantos, Laise Aline Martins Dos
dc.creatorOliveira, Wilma Helena de
dc.creatorFrança, Maria Eduarda Rocha de
dc.creatorLós, Deniele Bezerra
dc.creatorGabínio, Brennda Martins
dc.creatorPeixoto, Christina Alves
dc.date2019-04-11T15:06:55Z
dc.date2019-04-11T15:06:55Z
dc.date2018
dc.date.accessioned2023-09-26T22:36:59Z
dc.date.available2023-09-26T22:36:59Z
dc.identifierRODRIGUES, G. B. et al. A new diethylcarbamazine formulation (NANO-DEC) as a therapeutic tool for hepatic fibrosis. International Immunopharmacology, v. 64, p. 280–288, Nov. 2018.
dc.identifier1878-1705
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/32454
dc.identifier10.1016/j.intimp.2018.09.010
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8881055
dc.descriptionFundação de Amparo à Ciência e Tecnologia de Estado de Pernambuco (FACEPE/IBPG - 0163-2.09/14)
dc.descriptionThe aim of the present study was to assess if the uninterrupted and prolonged administration of nanoparticles containing diethylcarbamazine (NANO-DEC) would cause liver, kidney and heart toxicity and then analyze for the first time its action in model of liver fibrosis. Thus, NANO-DEC was administered in C57BL/6 mice daily for 48 days, and at the end the blood was collected for biochemical analyzes. In the long-term administration assay, the evaluation of serological parameters (CK-MB, creatinine, ALT, AST and urea) allowed the conclusion that NANO-DEC prolonged administration did not cause hepatic, renal and cardiac damage. For fibrosis assays, C57BL/6 mice were divided into six groups: 1) control (Cont); 2) carbon tetrachloride (CCl4); 3) CCl4 + DEC 25 mg/kg; 4) CCl4 + DEC 50 mg/kg; 5) CCl4 + NANO-DEC 5 mg/kg and 6) CCl4 + NANO-DEC 12.5 mg/kg. Carbon tetrachloride induced hepatic fibrosis observed through increased inflammatory (TNF-α, IL-1β, COX-2, NO and iNOS) and fibrotic markers (TGF-β and TIMP-1), changes in the hepatic morphology, high presence of collagen fibers and elevated serum levels of AST, ALT and ALP. Treatment with NANO-DEC exhibited a superior anti-inflammatory and anti-fibrotic effects compared to the DEC traditional formulation, restoring liver morphology, reducing the content of collagen fibers and serological parameters, besides decreasing the expression of inflammatory and fibrotic markers. The present formulation of nanoencapsulated DEC is a well tolerated anti-inflammatory and anti-fibrotic drug and therefore could be a potential therapeutic tool for the treatment of chronic liver disorders.
dc.description2050-01-01
dc.formatapplication/pdf
dc.languageeng
dc.rightsrestricted access
dc.subjectNanoencapsulation
dc.subjectDiethylcarbamazine
dc.subjectInflammation
dc.subjectFibrosis
dc.subjectAnimais
dc.subjectAnti-Inflamatórios / Farmacologia
dc.subjectTetracloreto de carbono
dc.subjectColágeno / análise
dc.subjectCreatinina / sangue
dc.subjectCicloxigenase 2 / análise
dc.subjectDietilcarbamazina / administração & dosagem
dc.subjectDietilcarbamazina / farmacologia
dc.subjectDietilcarbamazina / uso terapêutico
dc.subjectCompostos de Drogas
dc.subjectFígado / patologia
dc.subjectCirrose Hepática Experimental / quimioterapia
dc.subjectCirrose Hepática Experimental / patologia
dc.subjectMasculino
dc.subjectRatos
dc.subjectRatos, endogâmicos C57BL
dc.subjectNanopartículas
dc.subjectÓxido Nítrico / biossíntese
dc.titleA new diethylcarbamazine formulation (NANO-DEC) as a therapeutic tool for hepatic fibrosis
dc.typeArticle


Este ítem pertenece a la siguiente institución